MacroGenics, Inc. (MGNX) Covered Calls
Macrogenics Inc is engaged in the discovery and development of monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases.
You can sell covered calls on MacroGenics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MGNX (prices last updated Fri 4:16 PM ET):
| MacroGenics, Inc. (MGNX) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 3.24 | +0.03 | 3.20 | 3.35 | 443K | - | 0.2 |
| Covered Calls For MacroGenics, Inc. (MGNX) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Dec 20 | 3 | 0.25 | 3.10 | -3.2% | -40.3% | |
| Jan 17 | 3 | 0.00 | 3.35 | -10.4% | -66.6% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. It is focused on three therapeutic areas: Oncology, Autoimmune Disorders and Infectious Diseases. The company's proprietary technology platforms include Dual-Affinity Re-Targeting (DART) Therapeutics, which allow to incorporate multiple specificities within a single molecule; FC Optimization, enhances antibody-dependent functions; and Cancer Stem Cell, which provides a unique discovery tool to identify cancer targets shared by both tumor-initiating cells and differentiated cancer cells. Its infectious disease portfolio includes antibody-based therapeutics for the treatment of infectious diseases from pathogens, such as dengue, smallpox and H5N1. The company's autoimmune program, teplizumab, is an anti-CD3 antibody developed for the prevention and treatment of early onset diabetes. MacroGenics was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
| Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | SAVA covered calls | |
| 2. | SPY covered calls | 7. | XLF covered calls | 2. | CRVS covered calls | |
| 3. | EEM covered calls | 8. | TLT covered calls | 3. | APLT covered calls | |
| 4. | FXI covered calls | 9. | KWEB covered calls | 4. | ANAB covered calls | |
| 5. | IWM covered calls | 10. | AAPL covered calls | 5. | IREN covered calls | |
Want more examples? MGNI Covered Calls | MGPI Covered Calls
